Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Xenon Pharmaceuticals Inc.XENE · Entity 2602 | Director | May 18, 2021 | May 20, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Xenon Pharmaceuticals Inc.
Report date May 18, 2021 · Filed May 20, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 77,942 |
Ending reported balance
After 2021-05-18 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2021-05-18 · Exercise / conversion · Acquired 2,057 · Balance 71,770 F1: No shares were sold by the Reporting Person in connection with the exercise and the common shares issued as a result of the exercise are subject to the terms of a lock-up agreement executed by the Reporting Person in favor of the underwriters of the Company's public offering in March 2021. F2: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Row 2 · 2021-05-18 · Exercise / conversion · Acquired 1,028 · Balance 72,798 F1: No shares were sold by the Reporting Person in connection with the exercise and the common shares issued as a result of the exercise are subject to the terms of a lock-up agreement executed by the Reporting Person in favor of the underwriters of the Company's public offering in March 2021. F2: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Row 3 · 2021-05-18 · Exercise / conversion · Acquired 5,144 · Balance 77,942 F1: No shares were sold by the Reporting Person in connection with the exercise and the common shares issued as a result of the exercise are subject to the terms of a lock-up agreement executed by the Reporting Person in favor of the underwriters of the Company's public offering in March 2021. F2: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.87 · Expires 2021-06-30 | Direct | 0 |
Reported balance
After 2021-05-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-05-18 · Exercise / conversion · Disposed 2,057 · Balance 0 F2: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F3: The shares subject to the option fully vested on July 1, 2014. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.67 · Expires 2021-12-31 | Direct | 0 |
Reported balance
After 2021-05-18 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-05-18 · Exercise / conversion · Disposed 1,028 · Balance 0 F2: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F4: 1/3 of the shares subject to the Option vested on January 1, 2013 (the "First 2012 Vesting Commencement Date") and thereafter the remaining 2/3 of the shares subject to the Option vest each monthly anniversary of the First 2012 Vesting Commencement Date over the following 2 years. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.67 · Expires 2021-12-31 | Direct | 0 |
Reported balance
After 2021-05-18 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-05-18 · Exercise / conversion · Disposed 5,144 · Balance 0 F2: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F4: 1/3 of the shares subject to the Option vested on January 1, 2013 (the "First 2012 Vesting Commencement Date") and thereafter the remaining 2/3 of the shares subject to the Option vest each monthly anniversary of the First 2012 Vesting Commencement Date over the following 2 years. |
Filing footnotes · ownership attribution and instrument terms
F1: No shares were sold by the Reporting Person in connection with the exercise and the common shares issued as a result of the exercise are subject to the terms of a lock-up agreement executed by the Reporting Person in favor of the underwriters of the Company's public offering in March 2021.
F2: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
F3: The shares subject to the option fully vested on July 1, 2014.
F4: 1/3 of the shares subject to the Option vested on January 1, 2013 (the "First 2012 Vesting Commencement Date") and thereafter the remaining 2/3 of the shares subject to the Option vest each monthly anniversary of the First 2012 Vesting Commencement Date over the following 2 years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2021 Filed May 20, 2021 16:18 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,144 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0001209191-21-034400 · doc4.xml · derivative · entry 6 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 5,144 shares Expires 2021-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F4 · derivative.exercise_date: 1/3 of the shares subject to the Option vested on January 1, 2013 (the "First 2012 Vesting Commencement Date") and thereafter the remaining 2/3 of the shares subject to the Option vest each monthly anniversary of the First 2012 Vesting Commencement Date over the following 2 years. Read SEC document |
| May 18, 2021 Filed May 20, 2021 16:18 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,028 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0001209191-21-034400 · doc4.xml · derivative · entry 5 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 1,028 shares Expires 2021-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F4 · derivative.exercise_date: 1/3 of the shares subject to the Option vested on January 1, 2013 (the "First 2012 Vesting Commencement Date") and thereafter the remaining 2/3 of the shares subject to the Option vest each monthly anniversary of the First 2012 Vesting Commencement Date over the following 2 years. Read SEC document |
| May 18, 2021 Filed May 20, 2021 16:18 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,057 | $0.00 Strike: $3.87 | $0.00 |
DisclosureSEC source: 0001209191-21-034400 · doc4.xml · derivative · entry 4 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 2,057 shares Expires 2021-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F3 · derivative.exercise_date: The shares subject to the option fully vested on July 1, 2014. Read SEC document |
| May 18, 2021 Filed May 20, 2021 16:18 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 5,144 | $3.67 | $18,878.48 |
DisclosureSEC source: 0001209191-21-034400 · doc4.xml · nonDerivative · entry 3 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,942 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: No shares were sold by the Reporting Person in connection with the exercise and the common shares issued as a result of the exercise are subject to the terms of a lock-up agreement executed by the Reporting Person in favor of the underwriters of the Company's public offering in March 2021. F2 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| May 18, 2021 Filed May 20, 2021 16:18 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 1,028 | $3.67 | $3,772.76 |
DisclosureSEC source: 0001209191-21-034400 · doc4.xml · nonDerivative · entry 2 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,798 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: No shares were sold by the Reporting Person in connection with the exercise and the common shares issued as a result of the exercise are subject to the terms of a lock-up agreement executed by the Reporting Person in favor of the underwriters of the Company's public offering in March 2021. F2 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| May 18, 2021 Filed May 20, 2021 16:18 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 2,057 | $3.87 | $7,960.59 |
DisclosureSEC source: 0001209191-21-034400 · doc4.xml · nonDerivative · entry 1 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,770 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: No shares were sold by the Reporting Person in connection with the exercise and the common shares issued as a result of the exercise are subject to the terms of a lock-up agreement executed by the Reporting Person in favor of the underwriters of the Company's public offering in March 2021. F2 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| October 28, 2020 Filed Oct 29, 2020 16:27 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,144 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001209191-20-056229 · doc4.xml · derivative · entry 5 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 5,144 shares Expires 2020-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F3 · derivative.exercise_date: The shares subject to the option fully vested on December 31, 2013. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3. Read SEC document |
| October 28, 2020 Filed Oct 29, 2020 16:27 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,144 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001209191-20-056229 · doc4.xml · derivative · entry 4 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 5,144 shares Expires 2020-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F3 · derivative.exercise_date: The shares subject to the option fully vested on December 31, 2013. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3. Read SEC document |
| October 28, 2020 Filed Oct 29, 2020 16:27 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GiftCommon Shares | 10,288 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-056229 · doc4.xml · nonDerivative · entry 3 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,713 F2 · kind: The shares were gifted to family members that do not share the reporting person's household. Read SEC document |
| October 28, 2020 Filed Oct 29, 2020 16:27 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 5,144 | $3.76 | $19,341.44 |
DisclosureSEC source: 0001209191-20-056229 · doc4.xml · nonDerivative · entry 2 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| October 28, 2020 Filed Oct 29, 2020 16:27 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 5,144 | $3.76 | $19,341.44 |
DisclosureSEC source: 0001209191-20-056229 · doc4.xml · nonDerivative · entry 1 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,857 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 17:17 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,144 | $0.00 Strike: $3.52 | $0.00 |
DisclosureSEC source: 0001209191-20-035608 · doc4.xml · derivative · entry 2 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 5,144 shares Expires 2020-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F2 · derivative.exercise_date: The shares subject to the option fully vested on June 30, 2013. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 17:17 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 5,144 | $3.52 | $18,106.88 |
DisclosureSEC source: 0001209191-20-035608 · doc4.xml · nonDerivative · entry 1 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 17:19 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $13.11 | $0.00 |
DisclosureSEC source: 0001209191-20-033643 · doc4.xml · derivative · entry 1 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2030-05-31 F1 · derivative.exercise_date: One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 13:30 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,057 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0001209191-19-057754 · doc4.xml · derivative · entry 6 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 2,057 shares Expires 2020-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F4 · derivative.exercise_date: The shares subject to the option fully vested on June 30, 2013. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 13:30 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,144 | $0.00 Strike: $3.56 | $0.00 |
DisclosureSEC source: 0001209191-19-057754 · doc4.xml · derivative · entry 5 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 5,144 shares Expires 2019-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F3 · derivative.exercise_date: The shares subject to the option fully vested on December 31, 2012. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 13:30 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GiftCommon Shares | 2,057 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-057754 · doc4.xml · nonDerivative · entry 4 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,569 F2 · kind: The shares were gifted to family members that do not share the reporting person's household. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 13:30 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 2,057 | $3.51 | $7,220.07 |
DisclosureSEC source: 0001209191-19-057754 · doc4.xml · nonDerivative · entry 3 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,626 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 13:30 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GiftCommon Shares | 5,144 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-057754 · doc4.xml · nonDerivative · entry 2 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,569 F2 · kind: The shares were gifted to family members that do not share the reporting person's household. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 13:30 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 5,144 | $3.56 | $18,312.64 |
DisclosureSEC source: 0001209191-19-057754 · doc4.xml · nonDerivative · entry 1 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| September 16, 2019 Filed Sep 18, 2019 19:45 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $9.44 | $0.00 |
DisclosureSEC source: 0001209191-19-050172 · doc4.xml · derivative · entry 1 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2029-09-15 F1 · derivative.exercise_date: One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date. Read SEC document |
| May 21, 2019 Filed May 23, 2019 11:56 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,057 | $0.00 Strike: $3.21 | $0.00 |
DisclosureSEC source: 0000899243-19-014470 · doc4.xml · derivative · entry 2 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 2,057 shares Expires 2019-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F2 · derivative.exercise_date: The shares subject to the option fully vested on December 31, 2011. Read SEC document |
| May 21, 2019 Filed May 23, 2019 11:56 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 2,057 | $3.21 | $6,602.97 |
DisclosureSEC source: 0000899243-19-014470 · doc4.xml · nonDerivative · entry 1 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,569 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| December 21, 2018 Filed Dec 26, 2018 11:00 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GiftCommon Shares | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-18-008556 · ownership.xml · nonDerivative · entry 1 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,512 F1 · kind: The shares were gifted to family members that do not share the reporting person's household. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 16:40 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,144 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001171843-18-004796 · formfour.xml · derivative · entry 6 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 5,144 shares Expires 2018-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F4 · derivative.exercise_date: The shares subject to the option fully vested on December 31, 2011. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 16:40 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,057 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001171843-18-004796 · formfour.xml · derivative · entry 5 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 2,057 shares Expires 2018-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F3 · derivative.exercise_date: The shares subject to the option fully vested on June 30, 2011. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 16:40 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,144 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001171843-18-004796 · formfour.xml · derivative · entry 4 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 5,144 shares Expires 2018-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F2 · derivative.exercise_date: The shares subject to the option fully vested on May 31, 2011. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 16:40 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 5,144 | $3.07 | $15,792.08 |
DisclosureSEC source: 0001171843-18-004796 · formfour.xml · nonDerivative · entry 3 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 16:40 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 2,057 | $3.66 | $7,528.62 |
DisclosureSEC source: 0001171843-18-004796 · formfour.xml · nonDerivative · entry 2 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,368 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 16:40 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 5,144 | $3.70 | $19,032.80 |
DisclosureSEC source: 0001171843-18-004796 · formfour.xml · nonDerivative · entry 1 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,311 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| June 04, 2018 Filed Jun 5, 2018 16:42 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.20 | $0.00 |
DisclosureSEC source: 0001171843-18-004461 · form4.xml · derivative · entry 1 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2028-06-03 F1 · derivative.exercise_date: One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, and the balance of the total shares subject to the Option shall vest on the three year anniversary of the grant date. Read SEC document |
| June 19, 2017 Filed Jun 20, 2017 16:37 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,028 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0001171843-17-003707 · formfour.xml · derivative · entry 3 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 1,028 shares Expires 2017-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F3 · derivative.exercise_date: The shares subject to the option fully vested on June 30, 2010. Read SEC document |
| June 19, 2017 Filed Jun 20, 2017 16:37 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GiftCommon Shares | 1,028 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-17-003707 · formfour.xml · nonDerivative · entry 2 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,167 F2 · kind: The shares were gifted to family members that do not share the reporting person's household. Read SEC document |
| June 19, 2017 Filed Jun 20, 2017 16:37 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 1,028 | $3.51 | $3,608.28 |
DisclosureSEC source: 0001171843-17-003707 · formfour.xml · nonDerivative · entry 1 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 16:58 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 1,250 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001171843-17-003443 · formfour.xml · derivative · entry 2 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Shares · 1,250 shares Expires 2027-05-31 F2 · derivative.exercise_date: Options shall vest 100% on the one year anniversary of the grant date. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 16:58 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001171843-17-003443 · formfour.xml · derivative · entry 1 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Shares · 3,500 shares Expires 2027-05-31 F1 · derivative.exercise_date: One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, and the balance of the total shares subject to the Option shall vest on the three year anniversary of the grant date. Read SEC document |
| January 26, 2017 Filed Jan 27, 2017 17:27 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GiftCommon Shares | 7,201 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-17-000509 · formfour.xml · nonDerivative · entry 1 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,167 F1 · kind: The shares were gifted to family members that do not share the reporting person's household. Read SEC document |
| December 12, 2016 Filed Dec 13, 2016 16:57 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,403 | $0.00 Strike: $3.21 | $0.00 |
DisclosureSEC source: 0001171843-16-013622 · formfour.xml · derivative · entry 3 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 14,403 shares Expires 2016-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F3 · derivative.exercise_date: The shares subject to the option fully vested on December 31, 2009. Read SEC document |
| December 12, 2016 Filed Dec 13, 2016 16:57 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GiftCommon Shares | 7,202 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-16-013622 · formfour.xml · nonDerivative · entry 2 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,368 F2 · kind: The shares were gifted to family members that do not share the reporting person's household. Read SEC document |
| December 12, 2016 Filed Dec 13, 2016 16:57 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 14,403 | $3.21 | $46,233.63 |
DisclosureSEC source: 0001171843-16-013622 · formfour.xml · nonDerivative · entry 1 TARNOW MICHAEL M · CIK 0001263647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,570 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.